- Cart - 0 item(s)
- $0.00
Your shopping cart is empty!
- Chemistry
- Bioactive Molecules
- Anti-infection
- Apoptosis
- Autophagy
- Cell Cycle/DNA Damage
- Cytoskeleton
- Epigenetics
- GPCR/G Protein
- Immunology/Inflammation
- JAK/STAT Signaling
- MAPK/ERK Pathway
- Membrane Transporter/Ion Channel
- Metabolic Enzyme/Protease
- Neuronal Signaling
- NF-κB
- PI3K/Akt/mTOR
- PROTAC
- Protein Tyrosine Kinase/RTK
- Stem Cell/Wnt
- TGF-beta/Smad
- Vitamin D Related/Nuclear Receptor
- Others
- Methylation
- Cytoskeletal Signaling
- Natural Products
- Alkaloids
- Amino acid
- Anthraquinones
- Cerebrosides
- Chalcones
- Coumarins
- Diterpenoids
- Flavonoids
- Iridoids
- Lignans
- Lipids
- Miscellaneous
- Monoterpenoids
- Other terpenes
- Phenols
- Phenylpropanoids
- Quinones
- Saccharides
- Sesquiterpenoids
- Steroids
- Tetraterpenoids
- Thiophenes
- Triterpenoids
- Xanthones
- Polyphenols
- Stibene glucosides
- Oligose
- Anthocyanins
- Miscellaneous
- Chromones
- Terpenoids
- Indoles
- Procyanidins
- Aliphatics
- Botanical Cyclopeptides
- ADCs
- Antibodies
- Multiplex IHC
- Material Science
- Others
[CAS NO. 1405-87-4] Bacitracin
| Ships within | Stock | Price | Qty | Total |
Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.
| Catalog: | HY-107193 |
| Brand: | MCE |
| CAS: | 1405-87-4 |
Overview
| MDL | MFCD27976769 |
|---|---|
| Molecular Weight | 1422.69 |
| Molecular Formula | C66H103N17O16S |
| SMILES | [Bacitracin] |
Summary
Bacitracin is a polypeptide antibiotic against staphylococcal and pathogenic protozoa infections. Bacitracin inhibits cell wall biosynthesis and permeability through binding to the undecaprenyl pyrophosphate. Bacitracin inhibits macromolecular synthesis. Bacitracin is also a protein disulfide isomerase ( PDI ) inhibitor [1] [2] [3] .
In Vitro
Bacitracin (64 μg/mL, 24 h) together with Colistin shows antibacterial activity against
S. aureus
BA01611
[1]
.
Bacitracin (64 μg/mL, 1 or 2 h) damages the cell surface to grape-like cell clusters, and the cell boundaries are faint and unclear
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Bacitracin (0-100 mg/kg, intramuscular injection, daily for 12 consecutive days) shows anti-tumor efficacy in HCC model
[3]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | HCC model (MH134 cells implanted) [3] |
| Dosage: | 0, 10, 50, and 100 mg/kg |
| Administration: | Intramuscular injection (i.m), daily for 12 consecutive days. |
| Result: |
Decreased tumor volumes.
Decreased the percentage of PDI-stained vascular densities. |
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT00000635 | National Institute of Allergy and Infectious Diseases (NIAID)|Glaxo Wellcome |
Herpes Simplex|HIV Infections
|
Not Applicable | |
| NCT00671541 | Lahey Clinic |
Chronic Sinusitis
|
March 2006 | Phase 4 |
| NCT03213249 | Washington University School of Medicine|The Plastic Surgery Foundation |
Breast Implant Infection|Mammoplasty
|
July 25, 2017 | Phase 1 |
| NCT01516463 | Healthpoint |
Burn, Partial Thickness
|
March 2012 | Phase 4 |
| NCT01668030 | University of Louisville|Healthpoint |
Burns
|
February 2012 | Phase 4 |
| NCT03483363 | The University of Texas Health Science Center, Houston |
Surgical Site Infection
|
October 9, 2018 | Phase 4 |
| NCT02673229 | University of Kansas Medical Center |
Burn, Partial Thickness
|
January 2014 | Phase 4 |
| NCT01350102 | Susan Hassenbein|Milton S. Hershey Medical Center |
Diabetes, Type 1|Diabetes, Type 2|Foot Ulcer, Diabetic
|
February 2012 | Phase 4 |
| NCT00132600 | Mekos Laboratories AS |
Allergic Contact Dermatitis
|
April 2005 | Phase 2 |
| NCT04880655 | University of Tennessee|Medline Industries |
Burns|Partial-thickness Burn
|
August 3, 2021 | Not Applicable |
| NCT01222832 | Steward St. Elizabeth´s Medical Center of Boston, Inc. |
Paranasal Sinus Disease
|
July 2010 | Phase 2 |
| NCT02106962 | California Institute of Renal Research|Imprimis Pharmaceuticals, Inc. |
Arteriovenous Fistula
|
April 2014 | Phase 4 |
| NCT03929224 | Ascension South East Michigan |
Skin Infection
|
October 25, 2018 | Phase 4 |
| NCT01359735 | Healthpoint |
Non-melanoma Skin Cancer
|
May 2011 | Phase 2 |
| NCT03968835 | NYU Langone Health |
Finger Injuries|Amputation, Traumatic
|
December 24, 2018 | |
| NCT00705354 | Lahey Clinic |
Sinusitis|Chronic Sinusitis
|
January 2009 | Not Applicable |
Appearance
Solid
Source
Tracey I strain of Bacillus subtilis
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Solvent & Solubility
H 2 O : 100 mg/mL ( 70.29 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 0.7029 mL | 3.5145 mL | 7.0289 mL |
| 5 mM | 0.1406 mL | 0.7029 mL | 1.4058 mL |
| 10 mM | 0.0703 mL | 0.3514 mL | 0.7029 mL |
-
1.
Add each solvent one by one: PBS
Solubility: 100 mg/mL (70.29 mM); Suspended solution; Need ultrasonic
References
- [1] Si W, et al. Colistin Induces S. aureus Susceptibility to Bacitracin. Front Microbiol. 2018 Nov 20;9:2805.
- [2] Mohamed Faisal, et al. Bacitracin Inhibits the Oyster Pathogen Perkinsus marinus in Vitro and in Vivo. Journal of Aquatic Animal Health. Volume 11, 1999 - Issue 2.
- [3] Yu SJ, et al. Enhancement of hexokinase II inhibitor-induced apoptosis in hepatocellular carcinoma cells via augmenting ER stress and anti-angiogenesis by protein disulfide isomerase inhibition. J Bioenerg Biomembr. 2012 Feb;44(1):101-15.
Synonyms
Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.